Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lüftner

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Anticancer Research|June 9, 2001
Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancerG B Cook, I E Neaman, J L Goldblatt, et al.
Geburtshilfe Und Frauenheilkunde|March 5, 2016
ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015M Untch, D Augustin, J Ettl, et al.
Studies in Health Technology and Informatics|December 8, 1996
Quality monitoring, standardized documentation and management with a computerized system in oncologyT Beinert, M Dubiel, H G Mergenthaler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2023
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trialN Harbeck, P A Fasching, R Wuerstlein, et al.
Geburtshilfe Und Frauenheilkunde|February 17, 2015
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkP A Fasching, S Y Brucker, T N Fehm, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Anticancer Research|June 9, 2001
Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancerG B Cook, I E Neaman, J L Goldblatt, et al.
Geburtshilfe Und Frauenheilkunde|March 5, 2016
ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015M Untch, D Augustin, J Ettl, et al.
Studies in Health Technology and Informatics|December 8, 1996
Quality monitoring, standardized documentation and management with a computerized system in oncologyT Beinert, M Dubiel, H G Mergenthaler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2023
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trialN Harbeck, P A Fasching, R Wuerstlein, et al.
Geburtshilfe Und Frauenheilkunde|February 17, 2015
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkP A Fasching, S Y Brucker, T N Fehm, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
Pageof 5